Skip to main content

AptarGroup, Inc. (ATR) Stock Analysis

Buy WaitVALUE-TRAP 1/5Moderate Confidence

Healthcare · Medical Instruments & Supplies

Earnings in 0 days (2026-04-30). Expect elevated volatility around the report — consider waiting for post-earnings price action before new entries.

Wait for pullback to $122.90. Weak momentum — blocks BUY_NOW at $124.68. Engine's entry $122.90 (Support Atr Sticky) is the shallowest technical level that clears the 2:1 A.R:R minimum.

AptarGroup designs and manufactures drug and consumer product dosing, dispensing, and protection technologies including pumps, aerosol valves, elastomeric pharma packaging, and digital health solutions, serving pharmaceutical, fragrance, food, and personal care markets globally... Read more

$124.68+14.6% A.UpsideScore 5.1/10#16 of 25 Medical Instruments & Supplies
Entry $122.90(Support Atr Sticky)Stop $116.39Target $141.56(analyst − 13%)A.R:R 2.6:1Setup A.R:R 3.4:1
Analyst target$162.71+30.5%7 analysts
$141.56our TP
$124.68price
$162.71mean
$220

Wait for pullback to $122.90. Weak momentum — blocks BUY_NOW at $124.68. Engine's entry $122.90 (Support Atr Sticky) is the shallowest technical level that clears the 2:1 A.R:R minimum. Chart setup: No recognized chart pattern (not a breakout, bounce, continuation, recovery, falling knife, or range) — technicals mixed. Earnings in 0 days. Wait until post-earnings. Score 5.1/10, moderate confidence.

Passes 4/6 gates (favorable risk/reward ratio, clean insider activity, no SEC red flags, semi cycle peak clear). Fails on weak momentum and earnings proximity 0d<=7d. Suitability: moderate.

Thesis

Rewards
No bull case signals
Risks
No bear case signals

Key Metrics

P/E (TTM)20.9
P/E (Fwd)19.3
Mkt Cap$7.9B
EV/EBITDA11.3
Profit Mgn10.4%
ROE15.1%
Rev Growth13.5%
Beta0.49
Dividend1.54%
Rating analysts12

Quality Signals

Piotroski F8/9

Options Flow

P/C0.27bullish
IV57%elevated
Max Pain$110-11.8% vs spot

Concentration Risks(10-K Item 1A)

  • MEDIUMSuppliersingle-source resins and rubber components
    10-K Item 1A: 'we have historically sourced certain materials, especially some resins and rubber components for our Pharma segment, from a single source'

Material Events(8-K, last 90d)

  • 2026-03-17Item 5.02MEDIUM
    CEO Stephan Tanda notified the Board of intent to retire effective September 1, 2026. Gael Touya (President, Aptar Pharma) appointed as successor CEO effective same date. Clean handoff with named successor.
    SEC filing →

Model-generated analysis — not investment advice. Not a registered investment advisor. Past performance does not guarantee future results. Full disclaimer

Rating Breakdown

2 floor-breakers

Price action weak — below key moving averages, no momentum carry. Needs a base before trend-continuation setups apply.static

Macd
0.0
Volume
0.0
Ma Position
1.0
Rsi
3.5
Obv
10.0
Volume accumulation (rising OBV)Below 200-MA, MA slope -3.0%/30d — confirmed downtrend

Growth below the gate floor. Component breakdown shows what dragged the score down.static

Earnings Growth
0.0
Revenue Growth
5.9
GatesMomentum 2.9<4.5EARNINGS PROXIMITY 0d<=7dA.R:R 2.6 ≥ 1.5Insider activity: OKNo SEC red flagsSEMI CYCLE PEAK CLEARSuitability: Moderate
RSI
34 · Neutral
20D MA 50D MA 200D MAGOLDEN CROSSSupport $121.88Resistance $132.72

Price Targets

$116
$123
$142
A.Upside+13.5%
A.R:R2.6:1
Setup A.R:R (at entry)3.4:1

Position Sizing

ConvictionNone
Suggested %0.5%
Max %1%
RegimeCautious

Risk Alerts

! Earnings in 0 days - binary event risk
! Momentum score 2.9/10 — below 4.5 minimum
! EARNINGS_PROXIMITY:0d<=7d

Earnings

B
B
B
B
4/4 beats
Next Earnings2026-04-30 (0d)

Verdict History

reverse chrono — latest first
Loading history...
Verdicts are recorded on every nightly pipeline run. Rows capture transitions (verdict flips, score deltas ≥0.3, entry/TP/SL changes). Rows with a ▶ can be expanded to see the change reason. Aggregate cohort performance is tracked in the recommendation ledger.
Frequently Asked Questions
Is ATR stock a buy right now?

Wait for pullback to $122.90. Weak momentum — blocks BUY_NOW at $124.68. Engine's entry $122.90 (Support Atr Sticky) is the shallowest technical level that clears the 2:1 A.R:R minimum. Chart setup: No recognized chart pattern (not a breakout, bounce, continuation, recovery, falling knife, or range) — technicals mixed. Earnings in 0 days. Wait until post-earnings. Target $141.56 (+13.5%), stop $116.39 (−7.1%), Setup A.R:R 3.4:1. Score 5.1/10, moderate confidence.

What is the ATR stock price target?

Take-profit target: $141.56 (+14.6% upside). Target $141.56 (+13.5%), stop $116.39 (−7.1%), Setup A.R:R 3.4:1. Stop-loss: $116.39.

Is ATR overvalued or undervalued?

AptarGroup, Inc. trades at a P/E of 20.9 (forward 19.3). TrendMatrix value score: 5.9/10. Verdict: Buy (Wait for Entry).

What do analysts say about ATR?

12 analysts cover ATR with a consensus score of 4.1/5. Average price target: $163.

What does AptarGroup, Inc. do?AptarGroup designs and manufactures drug and consumer product dosing, dispensing, and protection technologies including...

AptarGroup designs and manufactures drug and consumer product dosing, dispensing, and protection technologies including pumps, aerosol valves, elastomeric pharma packaging, and digital health solutions, serving pharmaceutical, fragrance, food, and personal care markets globally with approximately 14,000 employees in ~20 countries. No single customer accounts for more than 4% of 2025 Net Sales.

Related stocks: WST (West Pharmaceutical Services, I) · MMSI (Merit Medical Systems, Inc.) · STVN (Stevanato Group S.p.A.) · RMD (ResMed Inc.) · ATRC (AtriCure, Inc.)